ISM6331 not checked
InSilico Medicine Hong Kong Limited
FollowEvery change as it happens, and a Monday email
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Dosage form: Capsule for oral administration. Frequency of administration: Once daily overall of treatment.”In the company’s words, NCT06566079 on ClinicalTrials.gov
- Tested for
- Malignant Mesothelioma, Metastatic Malignant Solid Tumor, Advanced Solid Tumor
- Main trialPhase 1/2
- “This is a Phase 1/2, open-label, multicenter, FIH study to evaluate the safety, tolerability, recommended Phase 2 dose (RP2D), PK/PD, and preliminary anti-tumor activity of ISM6331 in participants with advanced or metastatic mesothelioma or other Advanced solid tumors. The study consists of two parts, a dose escalation part (Part 1) and a dose selection expansion part (Part 2).”In the company’s words, NCT06566079 on ClinicalTrials.gov
Other drugs for Malignant Mesothelioma
- VT3989Vivace Therapeutics, Inc · Phase 3
- VolrustomigAstraZeneca · Phase 3
- EB-MF-CAR-NK-01Beijing Biotech · Phase 1/2
- Alintegimod7 Hills Pharma, LLC · Phase 1/2
- TYK-01054TYK Medicines · Phase 1/2
- A2B543A2 Biotherapeutics Inc. · Phase 1/2
Coming up1
- 31 Aug 2027Phase 1/2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1/2Recruiting | 31 Aug 2027 | Study of ISM6331 in Participants With Advanced/Metastatic Mesothelioma or Other Advanced Solid Tumors |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026